From Barrier to Breakthrough Scalable HSC-to-NK Manufacturing

Webinar | From Barrier to Breakthrough: Scalable HSC-to-NK Manufacturing

Thursday, January 29, 2026

Session 1: 10 a.m. CET | 2:30 p.m. IST | 5 p.m. HKT  

Session 2: 8 a.m. PST |  11 a.m. EST | 5 p.m. CET

ImmuneBridge and Sartorius developed a scalable hematopoietic stem cell (HSC) to natural killer (HSC-to-NK) cell manufacturing workflow using cord blood–derived CD34⁺ cells, an enriched source of highly primitive and proliferative HSCs. To overcome the limitations of traditional 2D culture systems, the companies leveraged an Ambr^® 15 stirred-tank bioreactor for systematic process development. They expanded the CD34⁺ HSCs and differentiated them into HSC-NK cells using GMP-grade stem cell growth (SCGM) medium.

This webinar will show how the companies used a design-of-experiments approach with MODDE^® software to optimize key process parameters and develop a feeder-free, scalable HSC-to-NK workflow.

The team’s work overcomes key bioprocessing challenges by optimizing process conditions for cord blood–derived starting material, reducing cytokine requirements to lower cost of goods, and establishing a controlled, feeder-free workflow suitable for scalable HSC-to-NK manufacturing.

What You Will Learn:

Learn how stirred-tank bioreactors enable controlled and scalable HSC-NK bioprocessing.
Discover how DOE-driven optimization improves HSC-NK expansion and differentiation.
See how GMP-grade raw materials enhance consistency and manufacturing.

Clear form data

Please Complete the Form

First Name *

Last Name *

Email *

Phone Number *

Company *

Job Title *

Address *

Country *

Postal Code *

I would like to sign up for newsletters from Sartorius (Sartorius AG and its affiliated companies) based of my personal interests.
I can revoke my consent at any time with effect for the future by sending an e-mail to unsubscribe@sartorius.com or by clicking on the "unsubscribe" link in e-mails I have received.

* These fields are required Information on the use of your data can be found in our privacy policy

Complete Form to Register

Rukmini Ladi

Segment Technology Manager, Cell Therapy, Advanced Therapies Solutions

Rukmini Ladi is a Segment Technology Manager for Cell Therapy at Sartorius with more than ten years of experience in cell and gene therapy process development. She supports global cell therapy developers in designing end-to-end, scalable workflows.

She specializes in designing and optimizing immune and stem cell therapy workflows for translational and manufacturing applications.

Rui Tostoes, PhD

Chief Technical Officer, ImmuneBridge

Rui Tostoes is an accomplished scientist and creative leader, with a passion for product and people development in cell therapy and bioprocessing. Through his work in MilliporeSigma and FloDesign Sonics, he is experienced in matrix work with functional areas of R&D, product development, and commercial in delivering successful product development and customer program execution.